Skip to main content

Dr. Vinay Prasad to Head FDA Vaccine, Biologics Division

Medically reviewed by Carmen Pope, BPharm. Last updated on May 7, 2025.

By I. Edwards HealthDay Reporter

WEDNESDAY, May 7, 2025 — The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research.

The division oversees vaccines and biologic medicines, including gene therapies, CNN reported.

Prasad is a hematologist-oncologist, a specialist in treating cancers of the blood. He has been a vocal critic of the U.S. government's response to the COVID-19 pandemic. He has questioned school closures, mask mandates and COVID booster shots.

He takes over from Dr. Peter Marks, who led the division for 13 years and played a major role in the COVID vaccine rollout. Marks resigned in March, writing in a letter that U.S. health secretary Robert F. Kennedy Jr. did not value science and transparency.

FDA Commissioner Dr. Marty Makary praised Prasad’s background, saying he has a "long and distinguished history in medicine" and highlighted his oncology research, according to CNN.

Prasad’s appointment comes as the FDA plans to require future vaccines to be tested through placebo-controlled trials.

Public health officials are also reconsidering recommendations for COVID vaccines for children — recommendations Prasad has questioned, because kids face lower risks from the virus than older people and those with weakened immune systems.

Amid news of his appointment, biotech stocks fell more than 5%. Sarepta Therapeutics, which makes a gene therapy for Duchenne muscular dystrophy, saw its stock drop nearly 25%.

Prasad had criticized the FDA’s approval of that treatment, Elevidys, saying its benefits were uncertain.

In a social media post earlier this year, Prasad wrote, “The FDA did nothing to speed gene therapy, other than talk about how they will use uncontrolled endpoints. But we want to speed effective gene therapy, not ineffective gene therapy. The FDA had no solution for that.”

Sources

  • CNN, May 6, 2025

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted May 2025

Read this next

FDA Chief: COVID Vaccine in Pregnancy Should Be Personal Choice

FRIDAY, May 30, 2025 — Federal health officials have pulled back a key recommendation that pregnant women get the COVID-19 vaccine — causing sharp criticism from...

Military Service Might Protect Against Depression

FRIDAY, May 30, 2025 — The mentally scarred, deeply depressed combat veteran is an indelible stereotype promoted by movies and TV. The post-traumatic stress and despair...

Parents Can Sense Potential Critical Illness In Their Kids, Study Says

FRIDAY, May 30, 2025 — A parent’s instincts regarding their child’s health usually are right on the money, even when they’ve taken the child to an ER, a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.